TP53 and acute myeloid leukemia: In vivo models of TP53-Y220C mutant AML treated with rezatapopt and venetoclax showed a significant reduction in leukemic burden and survival advantage compared to either agent alone, highlighting the translation potential of this precision-based therapy.